Arrowhead to Present at Piper Jaffray Healthcare Conference
Piper Jaffray Healthcare Conference 2013
PASADENA, Calif. -- November 26, 2013
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company
developing targeted RNAi therapeutics, today announced that President and CEO,
Christopher Anzalone, Ph.D., will present at the 25^th Annual Piper Jaffray
Healthcare Conference on Wednesday, December 4 at 1:30 p.m. EST at the New
York Palace Hotel.
A live webcast of the presentation can be accessed by visiting the News &
Events section of the company’s website,
http://www.arrowheadresearch.com/presentations. A replay will also be archived
on the website and available for 90 days.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company developing
targeted RNAi therapeutics. The company is leveraging its proprietary drug
delivery technologies to develop targeted drugs based on the RNA interference
mechanism that efficiently silence disease-causing genes. Arrowhead
technologies also enable partners to create peptide-drug conjugates that
specifically home to cell types of interest while sparing off-target tissues.
Arrowhead’s pipeline includes clinical programs in chronic hepatitis B virus
and obesity and partner-based programs in oncology.
For more information please visit http://www.arrowheadresearch.com, or follow
us on Twitter @ArrowRes. To be added to the Company's email list to receive
news directly, please send an email to firstname.lastname@example.org
Arrowhead Research Corporation
Vince Anzalone, CFA
The Trout Group
Press spacebar to pause and continue. Press esc to stop.